Stem cell therapy and PRP differ in what the syringe contains. PRP concentrates your platelets and growth factors; it contains no stem cells. Bone marrow aspirate (BMA) and microfragmented adipose tissue (MFAT) deliver a nucleated-cell population, including mesenchymal stem cells, that PRP alone cannot, the basis for describing cell-based treatment as the more potent biologic. Stated honestly: the randomized head-to-head for knee osteoarthritis read equivalent through two years. At Dynamic Athlete in Boulder, Colorado it is not either/or: Dynamic Stem Cell+ pairs physician-selected MFAT or BMA with high-dose PRP and FRP, performed by Aneesh Garg, DO, CAQ. The real decision is Dynamic PRP+ alone or the combined protocol.
Most pages treat this as two rival products. The clinical reality: the cells carry more potential, PRP carries the dose-dependent signal, and our strongest protocol combines them. Written by the physician who performs both.
The Decision
Start from the biology. Cell-based treatment brings what PRP cannot: nucleated cells, including mesenchymal stem cells. For tendinopathy and mild-to-moderate joint change, high-dose PRP alone is still often the right first step, and some cases are honestly surgical, which you will be told.
Then drop the either/or. Dynamic Stem Cell+ is not stem cells instead of PRP: it pairs the selected MFAT or BMA with high-dose PRP and FRP in one procedure. The real decision is Dynamic PRP+ alone or the combined protocol, matched to your imaging.
Key Takeaways
- The cells carry more potential. PRP concentrates platelets and growth factors but contains no stem cells; BMA and MFAT deliver nucleated cells, including mesenchymal stem cells, a population PRP cannot supply.
- It is not either/or here. Dynamic Stem Cell+ pairs physician-selected MFAT or BMA with high-dose PRP and FRP in one procedure. The real choice is Dynamic PRP+ alone or the combined protocol.
- The outcome record is stated honestly. The randomized head-to-head for knee osteoarthritis (The American Journal of Sports Medicine, 2022, 90 patients) read statistically equivalent through 2 years, bone marrow concentrate vs PRP alone.
- Dose still decides PRP. A 2021 randomized study tied durable benefit to a dose near 10 billion platelets. Dynamic PRP+ runs 12–20x baseline, over 10 billion, under live ultrasound.
- In our combined protocols, over 90% of our patients self-report a 75% or greater improvement, all without surgery. HSA and FSA dollars typically apply, and Cherry financing can spread the investment.
What Each Syringe Contains
Cells + platelets
PRP delivers concentrated platelets and growth factors, no stem cells. BMA and MFAT add nucleated cells, including MSCs. Dynamic Stem Cell+ delivers both, plus FRP.
How does a physician actually decide?
The decision runs on four variables.
What does each syringe actually deliver?
PRP is platelets and growth factors at whatever dose the preparation reached; it contains no stem cells. BMA and MFAT carry nucleated cells, including mesenchymal stem cells, characterized in donor-matched comparisons (Stem Cell Research & Therapy, 2018); microfragmentation preserves the fat’s repair-cell niche (Stem Cells Translational Medicine, 2018). That cell content is the potency case.
What did the head-to-head outcome trial find?
In the indication tested, the averages tied. In the Anz randomized trial (The American Journal of Sports Medicine, 2022), 90 knee-osteoarthritis patients received bone marrow concentrate or PRP alone; outcomes were statistically equivalent through two years. Cell content is potential; the outcome trial is one indication, one protocol.
Why combine them instead of choosing?
Because the biology is complementary, Dynamic Stem Cell+ is built as a combination: the selected MFAT or BMA brings the cells, high-dose PRP brings the signal at over 10 billion platelets, and Exosome-Containing Fibrin-Rich Plasma completes it, in one procedure. The exam-room question is not stem cells or PRP; it is Dynamic PRP+ alone or the combined protocol.
Who decides, and with what incentive?
The physician who evaluates you is the physician who treats you. Dr. Garg performs every procedure himself, under live ultrasound, and both paths run under one roof. Tendinopathy and early joint change often start with high-dose PRP alone; advanced change argues for the combined protocol; true end-stage disease gets a surgical consult, which we make.
How do high-dose PRP and stem cell compare?
| Property | Dynamic PRP+ | Dynamic Stem Cell+ |
|---|---|---|
| What it delivers | Platelets + growth factors; no stem cells | Nucleated cells incl. MSCs + high-dose PRP + FRP |
| Source | Your blood: platelets concentrated 12–20x, over 10 billion | Your bone marrow (BMA) or fat (MFAT), physician-selected |
| Best-fit picture | Tendinopathy, mild-to-moderate joint change | More advanced structural change |
| Evidence note | Ahead of cortisone at 3–9 months in pooled knee-OA trials | Equivalent to PRP alone at 2 years (knee OA); combined protocol untested there |
| Involvement | Blood draw; same-day | Same-day harvest under local anesthesia; no hospital |
| Always included | FRP; live ultrasound guidance | High-dose PRP + FRP; live ultrasound guidance |
| Cost tier | Lower; HSA/FSA, Cherry financing | Higher; quoted after evaluation |
The bottom line
The combined protocol is the point. The cells bring potential PRP cannot; high-dose PRP brings the signal; Dynamic Stem Cell+ delivers both. Whether your case needs that, or Dynamic PRP+ alone, is the evaluation’s job, not a headline’s.
Which three questions expose a default answer?
Print this. Ask it anywhere.
- Do you offer both PRP and cell-based options, and who performs each?
- What platelet dose, as a number, will my PRP contain?
- If stem cells are recommended, are they combined with high-dose PRP, or delivered alone?
Frequently asked questions
What is the difference between PRP and stem cell therapy?
PRP concentrates the platelets and growth factors from your own blood to signal repair in a tendon or joint. Stem cell therapy at Dynamic Athlete uses your own bone marrow concentrate (BMAC) or microfragmented fat (MFAT), which bring a cell population and structural support that PRP does not. PRP is often the right first step for many tendon and mild joint problems, while cell-based options are considered for more advanced cases. The physician matches the option to your diagnosis. Individual results vary.
Which one is right for my injury?
That depends on the tissue involved, the severity on imaging, your goals, and your health. Neither option is universally better. At the evaluation, Aneesh Garg, DO, CAQ reviews your case and recommends PRP, a cell-based option, or a different path, and explains the reasoning so you can decide with clear information. Individual results vary, and honest candidacy is part of the process.
Is stem cell therapy more effective than PRP?
More is not automatically better. For many tendon and early joint conditions, well-performed high-dose PRP is an appropriate and less involved choice. Cell-based options are considered when the clinical picture calls for them. The right answer is the one that fits your specific diagnosis, which is why the decision is made with a physician rather than by default. Individual results vary.
Are both performed by a physician at Dynamic Athlete?
Yes. Both PRP and stem cell procedures at Dynamic Athlete are performed by Aneesh Garg, DO, CAQ, under live ultrasound guidance. Physician performance supports accurate diagnosis, precise placement, and honest candidacy for either option. Request a consult at (303) 997-1733.
What did the head-to-head trial of stem cells vs PRP actually find?
The most direct comparison to date is the Anz prospective randomized trial, published in The American Journal of Sports Medicine in 2022. Ninety patients with symptomatic knee osteoarthritis (Kellgren-Lawrence grades 1-3) were randomized to a single injection of either bone marrow aspirate concentrate or PRP, and both groups improved with no statistically significant difference between them through 24 months. Two honest notes belong next to it. First, it compared bone marrow concentrate against PRP alone; it did not test the combined cell-plus-PRP protocol used at Dynamic Athlete. Second, an outcome trial in one indication does not erase the compositional difference: cell-based treatment delivers mesenchymal stem cell populations PRP does not contain. The choice should be made from your tissue, imaging, and goals rather than from a headline. Individual results vary.
When is PRP the wrong choice?
PRP has honest limits, and naming them is part of the job. Advanced bone-on-bone joint change, large structural tears with retraction, mechanical locking, and certain inflammatory or infectious conditions are pictures where an injection of any kind should not be the plan, and Dr. Garg refers those cases for surgical or specialist consultation. A low-dose PRP is also the wrong choice even for a good candidate: the randomized dose data links durable benefit to platelet counts a standard 2-3x preparation does not reach, which is why Dynamic PRP+ is built as a high-dose, multi-spin protocol. The evaluation exists to sort this before money is spent: some patients are told PRP is not their answer, and that honesty is deliberate.
Do stem cell procedures at Dynamic Athlete use donor cells?
No. Dynamic Stem Cell+ uses only your own tissue, harvested and delivered the same day: microfragmented adipose tissue (MFAT) from fat, or bone marrow aspirate (BMA) from the posterior pelvis, selected by Dr. Garg for your case. Nothing is cultured, expanded, or purchased from a donor bank. That matters for two reasons. Biologically, autologous same-day tissue is the approach studied in the comparative trials cited on this page. Practically, it keeps the procedure within the same-day, minimally manipulated framework rather than the territory of unapproved donor-cell products marketed by some vendors. If a clinic offers you a vial of donor stem cells for a joint, ask what it is, who regulates it, and what trial data supports it before you proceed.